{
    "clinical_study": {
        "@rank": "126193", 
        "acronym": "NAFLD", 
        "arm_group": [
            {
                "arm_group_label": "IDN-6556", 
                "arm_group_type": "Experimental", 
                "description": "IDN-6556 capsules, 25 mg BID"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo BID"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to\n      placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and\n      with abnormal liver tests"
        }, 
        "brief_title": "A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Nonalcoholic Steatohepatitis", 
            "Non-alcoholic Fatty Liver Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, randomized study to evaluate the effects of IDN-6556 on serum\n      transaminases and pharmacodynamics of IDN-6556 in subjects with non-alcoholic fatty liver\n      disease with elevated alanine aminotransferase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects of minimum adult legal age (according to local laws for\n             signing the informed consent document), able to provide written informed consent, and\n             understand and comply with the requirements of the study\n\n          -  Diagnosis of non-alcoholic fatty liver disease (NAFLD) as evidenced by imaging or\n             other diagnostic assessments\n\n          -  Alanine aminotransferase (ALT) levels \u22651.5 x ULN on at least two occasions, seven or\n             more days apart, during the Screening period\n\n          -  alpha-fetoprotein (AFP) \u2264 100 ng/mL\n\n          -  Hemoglobin \u226510 g/dL, a platelet count \u2265 100 x 109/L, and a white blood cell count \u2265\n             3.0 x 109/L\n\n          -  If on metformin, sulfonylureas, statins, or fibrates, subjects must be on a stable\n             dose of these drugs for at least three months prior to Screening and during the study\n\n        Exclusion Criteria:\n\n          -  Known infection with HIV, HCV, or HBV\n\n          -  Decompensated or severe liver disease as evidenced by one or more of the following:\n\n               1. Confirmed cirrhosis or suspicion of cirrhosis\n\n               2. Esophageal varices\n\n               3. Ascites\n\n               4. Suspicion of portal hypertension\n\n               5. Hospitalization for liver disease within 60 days of screening\n\n               6. Bilirubin >2 x ULN, or  ALT or AST > 10 x ULN\n\n          -  Inflammatory bowel disease\n\n          -  Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis\n             (RA)\n\n          -  Hepatocellular carcinoma (HCC) at entry into the study\n\n          -  History of or active non-liver malignancies other than curatively treated skin cancer\n             (basal cell or squamous cell carcinomas)\n\n          -  Significant systemic or major illness other than liver disease, including coronary\n             artery disease, cerebrovascular disease, pulmonary disease, renal insufficiency,\n             and/or serious psychiatric disease, that, in the opinion of the Investigator would\n             preclude the subject from participating in and completing the study\n\n          -  History or presence of alcohol abuse, defined as consumption of more than 210 mL of\n             alcohol per week (the equivalent of 14 4-ounce glasses of wine or 14 12-ounce\n             cans/bottles of beer or wine coolers), or other substance abuse within the prior two\n             years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077374", 
            "org_study_id": "IDN-6556-06"
        }, 
        "intervention": {
            "arm_group_label": "IDN-6556", 
            "description": "25 mg BID for 28 days", 
            "intervention_name": "IDN-6556", 
            "intervention_type": "Drug", 
            "other_name": [
                "emricasan", 
                "PF-03491390"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NAFLD", 
            "NASH"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic Rochester"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64131"
                    }, 
                    "name": "Kansas City Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newport News", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23602"
                    }, 
                    "name": "Bon Secours St Mary's Hospital of Richmond"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases", 
        "overall_contact": {
            "email": "gburgess@conatuspharma.com", 
            "last_name": "Gary Burgess, MD", 
            "phone": "+44 (0)7879602104"
        }, 
        "overall_contact_backup": {
            "email": "mhuyghe@conatuspharma.com", 
            "last_name": "MiRa Huyghe", 
            "phone": "858-457-7227"
        }, 
        "overall_official": {
            "affiliation": "Conatus Pharmaceuticals", 
            "last_name": "Gary Burgess, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in alanine aminotransferase from Baseline", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077374"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in aspartate aminotransferase from Baseline", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Levels of cCK18, flCK18, and caspase 3/7 will be evaluated", 
                "measure": "Changes in biomarkers from Baseline", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Change in homeostatic model assessment-insulin resistance from Baseline", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Conatus Pharmaceuticals Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Conatus Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}